Hernia Mesh Lawsuits in 2026: the Bard Recalls, Organ Perforation Claims and Settlement Status

As of October 2026, tens of thousands of hernia mesh lawsuits remain active in American courts. The C.R. Bard cases sit in federal multidistrict litigation in Ohio while the company's October 2024 settlement is still being administered, and separate trials against Covidien are producing some of the largest verdicts of the year. Here is the complete, verified 2026 picture.

Watch the explainer on our channel: Problem Solved on YouTube.

The Bard recalls that set the pattern

A recall is an FDA-supervised action to remove a risky product; a Class I recall, the most serious kind, means a reasonable probability of serious injury or death. The hernia mesh story began with Bard's Composix Kugel Mesh patch, whose "memory recoil ring" could break during implantation and pierce the bowel. Davol — Bard's subsidiary — recalled the X-Large patch in December 2005, expanded the recall in 2006 and 2007, and the FDA's recall record covers 31,761 units. Reported injuries included bowel perforation, bowel obstruction, and ring migration; one patient died. A global Kugel settlement followed in Rhode Island in 2014 — the University of Rhode Island reported roughly $200 million for about 2,000 claimants.

Key facts

  • 23,324 Bard actions pending in MDL 2846 (S.D. Ohio, Judge Edmund A. Sargus Jr.) as of October 1, 2026 — Source: JPML report via Schmidt & Clark.
  • BD's October 2024 agreement resolved about 38,000 Bard cases in Ohio and Rhode Island, reportedly worth over $1 billion — Source: ConsumerNotice.org. Individual terms confidential.
  • $88 million Covidien bellwether verdict on August 4, 2026 (Patterson v. Covidien: $77M to the plaintiff, $11M for loss of consortium) — Source: Reuters via Schmidt & Clark.
  • 25,904 hernia mesh cases pending across four manufacturer MDLs as of October 2026 — Source: ConsumerNotice.org.
  • Kugel Mesh recalls (December 2005, expanded 2006 and 2007) covered 31,761 units under FDA Class I records — Source: FDA via Schmidt & Clark.

Why organ perforation claims carry the most weight

Perforation means a hole or tear through an organ wall — most often the bowel. When mesh erodes into or breaks through the intestine, bacteria spill into the abdomen, causing peritonitis and sepsis; surgeons must then remove the mesh and repair or resect the damaged bowel. Related injuries include bowel obstruction, where mesh adheres to the intestine and blocks it, and enteric fistula, an abnormal passage to another organ or the skin. These demand emergency revision surgery, which is why they anchor the strongest claims. In the August 2026 Covidien bellwether, the jury heard the mesh's collagen barrier dissolved within about a week — far sooner than the expected month.

Where the Bard litigation stands in 2026

The Bard cases were consolidated in 2018 as MDL 2846 — In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation — in the Southern District of Ohio before Judge Edmund A. Sargus Jr. The center of gravity shifted on October 2, 2024, when Becton Dickinson — Bard's parent company — announced a confidential agreement resolving about 38,000 hernia mesh cases in Ohio and Rhode Island. In December 2024 the court created a qualified settlement fund, and special masters Ellen K. Reisman and John Jackson are running claim review; payments are still being processed, which is why 23,324 actions remain on the docket. For cases not covered, a court-supervised settlement process begins in January 2027, and new Bard cases continue to be filed in Rhode Island state court.

The verdicts that set everyone's expectations

A bellwether trial is a test case, chosen from hundreds or thousands of similar claims, whose outcome helps both sides price the rest. The Bard litigation ran four of them. The defense won the first; the plaintiff won the second with a $250,000 verdict and the fourth with a $500,000 verdict; and a Rhode Island state-court case produced the largest Bard verdict to date, $4.8 million. The headline of 2026, though, belongs to Covidien: on August 4, 2026, a Boston federal jury awarded $88 million to Larry and Tammy Patterson in the first Covidien bellwether, finding inadequate warning about how fast the mesh's collagen barrier dissolved. No punitive damages were awarded, and Medtronic — Covidien's parent — plans to challenge the verdict. Two more Covidien bellwethers are set for January 11 and March 2027.

Who may still qualify to file a claim

You may have a claim if you received a Bard or Davol polypropylene mesh implant and later suffered infection, migration or erosion, chronic pain, bowel obstruction, organ perforation, or hernia recurrence — especially if you needed revision surgery. Eligibility depends on the product, the medical evidence, and your state's filing deadline. Similar device litigation, like the Exactech knee and ankle implant recall cases, follows the same logic: an allegedly defective device plus a documented injury.

What happens next

The next milestone is January 2027, when the court-supervised process for unresolved Bard cases begins, while Covidien's bellwether trials continue. Because the manufacturers sit in separate MDLs, there will be no single global settlement. As in other device cases — from Truvada kidney claims to Paraquat Parkinson's litigation — preserve every medical record and get legal advice before any deadline passes.

Who Benefits From This — and Who Does Not

Hernia mesh litigation is still moving in 2026 — but it rewards a specific injury history, not merely having had mesh implanted, and the Bard settlement track differs sharply from the Covidien trial track.

Who benefits

  • Recipients of Bard or Davol polypropylene mesh with serious complications: You may have a claim if you received a Bard or Davol polypropylene mesh implant and later suffered infection, migration or erosion, chronic pain, bowel obstruction, organ perforation, or hernia recurrence — especially if you needed revision surgery.
  • Patients whose cases fall under the Bard settlement process: BD’s October 2024 agreement resolved about 38,000 Bard cases in Ohio and Rhode Island, reportedly worth over $1 billion, with a qualified settlement fund created in December 2024 and special masters running claim review — while 23,324 Bard actions remain pending in MDL 2846 as of October 1, 2026.
  • Patients with perforation-type injuries: When mesh erodes into or breaks through the intestine, bacteria spill into the abdomen causing peritonitis and sepsis, and surgeons must remove the mesh and repair or resect the bowel — which is why these injuries anchor the strongest claims, as the August 2026 Covidien bellwether’s $88 million verdict illustrates.

Who does not benefit

  • Recipients with no complications: Having mesh implanted, without infection, migration, erosion, chronic pain, obstruction, perforation, or recurrence, does not by itself match the qualifying injury pattern described in this article.
  • Anyone expecting a fixed payout figure: Individual settlement terms are confidential, verdicts vary enormously — Bard bellwethers produced $250,000, $500,000, and a $4.8 million Rhode Island verdict — and most settlements are confidential, so advertised figures are a poor guide to any individual claim.
  • People who assume the Bard litigation is finished: Payments are still being processed, 23,324 actions remain on the docket, and for cases not covered by the agreement a court-supervised settlement process begins in January 2027 — the story is not closed.

For how a different implant recall compares, see our Exactech knee and ankle implant recall guide for 2026.

Frequently asked questions

Is the Bard hernia mesh settlement finished?

Largely. Becton Dickinson's October 2024 agreement resolved about 38,000 Bard cases in Ohio and Rhode Island; individual terms remain confidential. Payments are still being processed, and a court-supervised process for unresolved cases begins in January 2027.

Can I still file a hernia mesh lawsuit in 2026?

Yes. New Bard cases are still being filed, mostly in Rhode Island state court. Deadlines vary by state, so speak with a qualified attorney promptly.

Do I need to have had revision surgery to qualify?

Not necessarily, though documented revision surgery usually strengthens a claim. Cases have also been built on infections, migration or erosion, chronic pain, bowel obstruction, and hernia recurrence. Medical records connecting the injury to the mesh are essential.

How much compensation could I receive?

Compensation varies widely by case, and most settlements are confidential, so no payout can be promised. Past results range from a $250,000 Bard bellwether verdict and a $4.8 million Rhode Island verdict to the $88 million August 2026 Covidien bellwether verdict — each case is judged on its own evidence.

Who benefits from following the hernia mesh litigation — and who does not?

Recipients of Bard or Davol polypropylene mesh who later suffered infection, migration or erosion, chronic pain, bowel obstruction, organ perforation, or hernia recurrence benefit most — especially if revision surgery was needed — as do patients whose cases fall under the Bard settlement process, where about 38,000 cases were resolved in October 2024 while 23,324 actions remain pending in MDL 2846. It does not benefit recipients with no complications, anyone expecting a fixed payout figure — individual terms are confidential and verdicts range from $250,000 to $4.8 million in Bard bellwethers — or anyone who assumes the litigation is finished, since payments are still being processed and a further court-supervised process begins in January 2027. The full breakdown is in the section “Who Benefits From This — and Who Does Not” above.

How do I start checking whether I may have a hernia mesh claim?

First, confirm the product: whether you received a Bard or Davol polypropylene mesh implant, using your surgical records. Second, match your history against the qualifying pattern — infection, migration or erosion, chronic pain, bowel obstruction, organ perforation, or hernia recurrence, especially with revision surgery. Third, note which track applies: Bard cases sit in federal multidistrict litigation in Ohio (MDL 2846) with a settlement fund under administration, while Covidien cases are proceeding through bellwether trials, with two more set for January 11 and March 2027 — then discuss your specific records with a qualified attorney, since individual eligibility turns on your own medical history.

Disclaimer: This article is general information only and is not legal or financial advice. Consult a qualified professional about your situation.

Watch on YouTube

Problem Solved on YouTube